Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Directorate Change

14 Dec 2012 07:00

RNS Number : 5188T
Immunodiagnostic Systems Hldgs PLC
14 December 2012
 



14 December 2012

 

Immunodiagnostic Systems Holdings plc

 

Chris Yates appointed as Group Finance Director

 

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces that Chris Yates has been appointed Group Finance Director, with effect from 4th March 2013. 

 

Chris Yates, aged 38, joins IDS from private equity backed Nexus Vehicle Holdings Limited, where he has acted as Group Finance Director since January 2009. During his time at Nexus, as well as holding overall responsibility for finance and human resources, Chris oversaw the acquisition of Adapted Vehicle Hire Limited in May 2010.

 

From 2005 to 2007, Chris held the position of Group Finance Director at Cozart plc, allowing him to gain significant experience in the medical diagnostics industry.  During his time at Cozart, Chris led the acquisitions of four European companies: Spinreact SA (Spain), HL Scandinavia (Sweden), Nemesis Scientific Limited (UK) and Medib Skandinavien AB (Sweden) creating a pan-European medical diagnostics group. Cozart was subsequently acquired by Concateno plc (now part of Alere Inc.) in October 2007 for £64m in cash.

 

In 2008 Chris then furthered his industry expertise by acting as Co-founder and Finance Director of private specialist diagnostics company, Abingdon Health Limited.

 

From 4th March 2013 Barry Hextall, currently interim Group Finance Director, will resume his previous role as Deputy Group Finance Director.

 

Patrik Dahlen, Chief Executive Officer of IDS, commented: "It is a pleasure to announce that Chris Yates will be joining our team as Group Finance Director. As well as having a strong financial background, I am confident that Chris's knowledge and experience in the diagnostics industry will prove to be invaluable to IDS during this crucial time in the evolution of the business as a leading innovator and provider of specialist assays and diagnostic testing kits.

 

"I would also like to thank Barry Hextall for his continued support as Interim Finance Director."

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Patrik Dahlen, Chief Executive Officer

 

 

 

 

 

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

 

Dr Vijay Barathan

 

 

 

FTI Consulting

Tel : +44 (0)207 831 3113

Ben Atwell

 

Simon Conway

 

Mo Noonan

 

 

 

Additional Information

Christopher Henry Francis Yates (aged 38) currently holds and has held (including all appointments during the five years preceding the date of this announcement), the following directorships and partnerships, other than the Company:

 

Current directorships:

Adapted Vehicle Hire Limited

Forsite Diagnostics Limited

Nexus VRM Limited

Nexus Vehicle Management Ltd

Nexus Vehicle Holdings Limited

Abingdon Health LTD

 

Chris currently has no shares in the Company and there are no other disclosures required pursuant to Rule 17 and Schedule 2; paragraph (g) of the AIM Rules for Companies.

 

About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.

 

http://www.idsplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGGGQGPUPPPWW
Date   Source Headline
28th Jun 201612:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20161:42 pmRNSDirector/PDMR Shareholding
22nd Jun 20167:45 amRNSAnnual Report and Accounts
22nd Jun 20167:00 amRNSPreliminary Results
9th Jun 20167:00 amRNSUpdate re Royalty Revenues
20th May 20169:20 amRNSHolding(s) in Company
6th May 201610:30 amRNSLaunch of IDS-iSYS 17-OH Progesterone assay
25th Apr 20167:00 amRNSFull Year Trading Update
8th Jan 20167:00 amRNSRelocation of Automated related Assay Activity
4th Jan 20167:30 amRNSPaul Martin joins as Group Finance Director
18th Dec 20159:43 amRNSLaunch of Salivary Cortisol Hypertension Assay
30th Nov 201510:41 amRNSHolding(s) in Company
24th Nov 20157:00 amRNSHalf Yearly Report
22nd Oct 20152:22 pmRNSDirectorate Change
21st Oct 20155:00 pmRNSHolding(s) in Company - Replacement
20th Oct 20152:23 pmRNSDirectorate Change
13th Oct 20157:00 amRNSTrading Statement
8th Oct 20154:40 pmRNSHolding(s) in Company
1st Oct 201512:05 pmRNSTotal Voting Rights
30th Sep 20152:05 pmRNSHolding(s) in Company
15th Sep 20154:32 pmRNSAdditional Listing
4th Aug 20152:43 pmRNSResult of AGM
4th Aug 20157:00 amRNSAGM Statement
29th Jun 20153:18 pmRNSRe Report and Accounts and AGM - Replacement
29th Jun 201511:59 amRNSRe Report and Accounts and AGM
29th Jun 20157:15 amRNSDirectorate Change
23rd Jun 20157:00 amRNSFinal Results
12th Jun 20154:00 pmRNSBoard Appointment
10th Jun 20157:00 amRNSDirectorate Change
29th May 20157:00 amRNSTrading Statement
21st Apr 20157:00 amRNSTrading Statement
2nd Apr 20157:43 amRNSPatricio Lacalle Joins as Chief Executive Officer
9th Feb 201510:30 amRNSHolding(s) in Company
3rd Feb 20157:00 amRNSDirectorate Change
6th Jan 20155:04 pmRNSAdditional Listing
5th Jan 20155:10 pmRNSAdditional Listing
24th Dec 20141:30 pmRNSDirectorate Change
19th Dec 201410:47 amRNSHolding(s) in Company
19th Dec 20148:40 amRNSHolding(s) in Company
18th Dec 20149:30 amRNSDirector/PDMR Shareholding
15th Dec 20145:13 pmRNSHolding(s) in Company
12th Dec 20147:00 amRNSLaunch of 1,25-Dihydroxy Vitamin D Assay
8th Dec 20143:38 pmRNSHolding(s) in Company
4th Dec 20145:36 pmRNSDirectorate Change
4th Dec 20144:27 pmRNSDirector/PDMR Shareholding
25th Nov 20147:00 amRNSDirectorate Change
25th Nov 20147:00 amRNSHalf Yearly Report
24th Nov 20145:20 pmRNSPatrik Dahlen Resigns as CEO
14th Oct 20147:00 amRNSTrading Update
15th Sep 20147:00 amRNSUpdate on current trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.